·±ÌåÖÐÎÄ  
 
°æÖ÷£ºbob
 ¡¤ ¾ÅÑôÈ«ÐÂÃâÇåÏ´ÐͶ¹½¬»ú È«ÃÀ×îµÍ
 
¡°ÍòÄÜ¡±ÊÜÌåÊÊÅäÆ÷--йÚSµ°°× 2
Ëͽ»Õß:  2023Äê08ÔÂ20ÈÕ08:13:30 ÓÚ [ÊÀ½çʱÊÂÂÛ̳] ·¢ËÍÇÄÇÄ»°

½ÓÐø£º¡°ÍòÄÜ¡±ÊÜÌåÊÊÅäÆ÷--йÚSµ°°× 1


5¡¢HS/HSPG


HS£ºheparan sulfate£¬ÁòËáÒÒõ£¸ÎËØ£¬ÊÇÒ»ÖÖ´ø¸ß¸ºµçºÉµÄ¸ßËáÐÔÁ´×´¶àÌÇ£¬Ò²ÊÇÒ»ÖÖÁòËữµÄÌÇ°·¾ÛÌÇ£¨glycosaminoglycans£¬GAGs£©¡£

HSÔÚÈËÀàºÍ¶¯Îï×éÖ¯ÖÐÆÕ±é´æÔÚ£¬Ëü¿ÉÄÜ´æÔÚ/±í´ïÓÚÈ˺Ͳ¸È鶯ÎïËùÓÐϸ°ûÀàÐ͵ıíÃ棬ÒÔ¼°Ï¸°ûÍâ»ùÖʺͻùµ×ĤÖС£HS¾ßÓзǷ²µÄ½á¹¹¶àÑùÐÔ£¬Äܹ»Óë¸÷ÖÖµ°°×¡¢¶àëÄÏ໥×÷Óò¢·¢»Ó²»Í¬µÄ¹¦ÄÜ¡£HS¿ÉÓëÃâÒßϵͳµÄ¶àÖֳɷÖÏ໥×÷Óã¬ÈçÓë¶àÖÖϸ°ûÒò×Ó¼°Ä³Ð©Tϸ°ûÊÜÌå½áºÏ£¬ÔÚÃâÒßϵͳÖз¢»Ó¶à·½ÃæµÄÖØÒª×÷Óá£HSÒѱ»Ö¤Ã÷¿ÉÒÔµ÷½Ú°×ϸ°û·¢Óý¡¢°×ϸ°ûÎÈ̬¡¢°×ϸ°ûǨÒÆ£¬²ÎÓëTϸ°û¹²´Ì¼¤¡¢ÃâÒß¼¤»îºÍÑ×Ö¢¹ý³Ì¡£HS»¹¿ÉÄܵ÷½ÚÃâÒßÍ»´¥Öйؼü³É·ÖµÄ¿ÉÓÃÐÔ£¬²¢ÔÚÐźŴ«µ¼¡¢Ï¸°û¼äͨѶÖз¢»Ó×÷Óá£

HSͨ³£¸½×ÅÔÚ¸÷ÖÖºËÐĵ°°×ÉÏÐγÉHSPG£¨heparan sulfate proteoglycans£©£¬¼´ÁòËáÒÒõ£¸ÎËص°°×¾ÛÌÇ£¬»ò³ÆΪHS-µ°°×¾ÛÌÇ£¨HS-proteoglycans£©¡£ÔÚHSPGÖУ¬ºËÐĵ°°×ÓëHS¶àÌÇÁ´Í¨¹ý¹²¼Û¼üÁ¬½Ó£¬Ò»¸öºËÐĵ°°×¿ÉÁ¬½Ó1¸ö¡¢2¸ö»ò3¸öHS¶àÌÇÁ´¡£HSPGÄܹ»Í¨¹ý½á¹¹Òì³£¶àÑùµÄHSÁ´½áºÏ´óÁ¿ÅäÌ壬°üÀ¨Éú³¤Òò×Ó¡¢ÐÎ̬·¢ÉúËØ¡¢Ï¸°ûÒò×Ó¡¢Ç÷»¯Òò×Ó¡¢Ã¸¡¢»ùÖʵ°°×£¬ÒÔ¼°Ï¸¾úºÍ²¡¶¾µÈ²¡Ô­Ìå¡£HSPGͨ¹ý¹ã·ºµÄ½áºÏÄÜÁ¦ÔÚ¶àÖÖϸ°û¹ý³ÌÖз¢»Ó¹Ø¼ü£¨µ÷½Ú£©×÷Óã¬Èçϸ°ûÕ³¸½¡¢ÊÜÌ弤»î¡¢Ï¸°û¹Ç¼Ü×é×°¡¢Ï¸°ûÍâ»ùÖÊÖØËÜ¡¢ÄÚÍÌ×÷Óá¢Ï¸°û¼ä´®ÈÅ¡¢ÐźŴ«µ¼¡¢¸ÐÖª×éÖ¯ËðÉ˺ͽ鵼Ñ×Ö¢·´Ó¦µÈµÈ¡£

×ÜÖ®£¬HS/HSPGÔÚ×éÖ¯ÄÚÆÕ±é±í´ïÇÒ¹¦Äܷḻ£¬ÔÚÖÚ¶àÉúÀí¡¢²¡Àí¹ý³ÌÖз¢»ÓÖØÒª×÷Ó㬶þÕߵĺܶàÉúÀí¡¢²¡Àí×÷ÓõÈͬ»ò¸ß¶ÈÏà¹Ø¡£

HS/HSPGÊǶàÖÖ²¡¶¾µÄ¸ÐȾÊÜÌå»ò¸½×ÅÒò×Ó£¬ÕâЩ²¡¶¾°üÀ¨£ºHIV£¨°¬×̲¡²¡¶¾£¬ÊôÓÚÄæת¼²¡¶¾¿ÆÂý²¡¶¾Êô£©¡¢HSV-1/2£¨herpes simplex virus 1/2£¬µ¥´¿ðåÕ¶¾ÑªÇåÐÍ1/2£¬¶þÕßÊôÓÚðåÕ¶¾¿Æ£©¡¢HCoV-NL63£¨È˹Ú×´²¡¶¾NL63£¬ÊôÓÚ¹Ú×´²¡¶¾¦ÁÆ×ϵ£¬Ð¹ÚÊôÓÚ¦ÂÆ×ϵ£©¡¢HCV£¨hepatitis C virus£¬±ûÐ͸ÎÑײ¡¶¾£¬ÊôÓڻƲ¡¶¾¿Æ¸ÎÑײ¡¶¾Êô£©¡¢HRSV£¨Human Respiratory Syncytial Virus£¬ÈËÀàºôÎüµÀºÏ°û²¡¶¾£¬ÊôÓÚ¸±ð¤Òº²¡¶¾¿Æ·Î²¡¶¾Êô£©¡¢Sindbis virus£¨SINV£¬ÐÁµÂ±È˹²¡¶¾£¬ÊôÓÚÅûĤ²¡¶¾¿Æ¼×²¡¶¾Êô£¬Ò»ÖÖÓÉÎÃ×Ó´«²¥µÄ·Ö²¼×î¹ã·ºµÄ³æý²¡¶¾£©¡¢MCPyV£¨Merkel cell polyomavirus£¬Ä¬¿Ë¶ûϸ°û¶àÁö²¡¶¾£¬ÊôÓÚ¶àÁö²¡¶¾¿Æ£¬Ò»ÖÖº±¼ûµÄ¸ß¶ñÐÔƤ·ô°©µÄÖ²¡Òò£©µÈµÈ¡£SARS-CoV-1Ò²ÓÐÒ»¶¨³Ì¶ÈµÄHS/HSPG½áºÏÄÜÁ¦£¬µ«HS/HSPG¿ÉÄܸÉÈŶø²»ÊÇ´Ù½øSARS-CoV-1µÄ¸ÐȾ¡£

ÔÚSARS-CoV-2¸ÐȾÖУ¬HS/HSPGÊÇACE2µÄ¹²ÊÜÌå/¸¨ÖúÊÜÌ壬¿ÉÏÔÖø´Ù½øACE2ÒÀÀµÐÔ¸ÐȾ¡£ÔÚ¸ÐȾϸ°ûʱ£¬SARS-CoV-2µÄSµ°°×»áͬʱ½áºÏACE2ºÍHS/HSPG¡£

ÂÛÎÄÒÀ¾ÝÒ»

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
SARS-CoV-2¸ÐȾÒÀÀµÓÚϸ°ûÁòËáÒÒõ£¸ÎËغÍACE2
https://www.cell.com/cell/fulltext/S0092-8674(20)31230-7

ÂÛÎÄ¡°Highlights¡±²¿·Ö£¨ÒëÎÄ£©£º

a£©SARS-CoV-2´ÌÍ»µ°°×ͨ¹ýRBDÓëÁòËáÒÒõ£¸ÎËغÍACE2Ï໥×÷Óã»

b£©ÁòËáÒÒõ£¸ÎËشٽøSARS-CoV-2 Spike-ACE2Ï໥×÷Óã»

c£©SARS-CoV-2¸ÐȾ¹²Í¬ÒÀÀµÓÚÁòËáÒÒõ£¸ÎËغÍACE2£»

d£©¸ÎËغͷǿ¹ÄýÑÜÉúÎï¿É×è¶ÏSARS-CoV-2½áºÏºÍ¸ÐȾ¡£

ÂÛÎľßÌåÒªµã£º

1¡¢SARS-CoV-2 Spike£¨´ÌÍ»µ°°×¡¢Sµ°°×£©Í¨¹ýRBD£¨Receptor Binding Domain£¬ÊÜÌå½áºÏÓò£©ÓëÁòËáÒÒõ£¸ÎËؼ°ACE2Ï໥×÷Ó㬵¥¸öRBD¿ÉÒÔÔÚϸ°û±íÃæͬʱ½áºÏHSºÍACE2¡£

2¡¢·ÖÎö±íÃ÷£¬SARS-CoV-2 RBDÓëHSµÄ½áºÏÄÜÁ¦£¬ÏÔÖøÇ¿ÓÚSARS-CoV-1£¨SARS-CoV£©RBDÓëHSµÄ½áºÏÄÜÁ¦¡£ÈçÏÂͼËùʾ£º

S0092-8674(20)31230-7_gr2_lrg_50p_B.JPG

SARS-2 RBD¡¢SARS-1 RBDµÄHS½áºÏÄÜÁ¦¶ÔÕÕ

SARS-2´ú±íSARS-CoV-2¡£

BSA £¬Bovine Serum Albumin£¬Å£ÑªÇå°×µ°°×¡£Immobilized heparin-BSAΪţѪÇå°×µ°°×ÅàÑøÒºÖеĹ̶¨»¯¸ÎËØ¡£

heparin£¨¸ÎËØ£©ÊÇ·Ê´óϸ°û£¨Mast cell£©ºÍÊȼîÐÔÁ£Ï¸°û£¨basophil cells£©µÄ·ÖÃÚÎ×îÔçÊÇ´Ó¶¯Îï¸ÎÔàÖзÖÀë¡¢·¢Ïֵġ£heparin£¨¸ÎËØ£©¡¢heparan sulfate£¨ÁòËáÒÒõ£¸ÎËØ£©¶¼ÊÇÁòËữµÄÌÇ°·¾ÛÌÇ£¬ËüÃǵĽṹ·Ç³£ÏàËÆ£¬heparinÒ²ÄܽáºÏSARS-2¡¢SARS-1µÄRBD£¬µ«Ëü²»ÊÇÒ»ÖÖϸ°ûĤÊÜÌå¡£heparin¿É×÷ΪÓëHS¾ºÕùSARS-2 S/RBDµÄ¸ÉÈÅ¡¢ÒÖÖƼÁ¡£

3¡¢SARS-CoV-2 HS½áºÏÄÜÁ¦µÄÏÔÖøÌáÉý£¬ÊÇͨ¹ýÁ½¸ö°±»ùËáÌæ´úThr444LysºÍGlu354Asn»ñµÃµÄ¡£

ÕâÒâζ×Å£¬»ùÓÚSARS-CoV-1²»ÄÑ»ñµÃSARS-CoV-2µÄHS½áºÏÄÜÁ¦¡£ÓбØÒª¶Ô´Ë¶à×öһЩ˵Ã÷£¨ÎÞÐëÑо¿¼¼Êõϸ½ÚµÄ¶ÁÕß¿ÉÌø¹ý£©¡£

Èý×ÖĸËõдThr´ú±íËÕ°±ËᣨThreonine£©£¬Æäµ¥×ÖĸËõдΪT£¬¼´Thr=T£»Lys´ú±íÀµ°±ËᣨLysine£©£¬Æäµ¥×ÖĸËõдΪK£¬¼´Lys=K¡£Ìæ´úThr444Lys=T444K¡£

Glu´ú±í¹È°±ËᣬÆäµ¥×ÖĸËõдΪE£¬¼´Glu=E£»Asn´ú±íÌ춬õ£°·£¬Æäµ¥×ÖĸËõдΪN£¬¼´Asn=N¡£Ìæ´úGlu354Asn=E354N¡£

¹ØÓÚ20ÖÖ³£¼û°±»ùËá¼°Ëõд£¬¿É²ÎÔÄ£º
°±»ùËá ¨C ά»ù°Ù¿Æ£¬×ÔÓɵİٿÆÈ«Êé.htm
https://zh.wikipedia.org/zh-hans/%E6%B0%A8%E5%9F%BA%E9%85%B8

Ç°ÃæµÄ°±»ùËá¶ÔÓ¦SARS-CoV-1£¬ºóÃæµÄ°±»ùËá¶ÔÓ¦SARS-CoV-2£¬ÖмäµÄÊý×ÖÊÇSARS-CoV-2 Sµ°°×°±»ùËáÐòÁеÄÐòºÅ¡£

Ìæ´úThr444Lys£¨T444K£©±íʾ£¬Ïà¶ÔSARS-1£¬SARS-2 Sµ°°×µÄµÚ444°±»ùËáλµã·¢ÉúÁË´ÓËÕ°±ËᣨT£¬Thr£©µ½Àµ°±ËᣨK£¬Lys£©µÄÌæ´ú»òÍ»±ä¡£»òÕß˵£¬SARS-2 Sµ°°×°±»ùËáÐòÁеĵÚ444°±»ùËáÊÇÀµ°±ËᣨK£¬Lys£©£¬¶øÕâһλµãÔÚSARS-1 Sµ°°×¶ÔӦλµã´¦µÄ°±»ùËáÊÇËÕ°±ËᣨT£¬Thr£©¡£ÓÉÉÔºóµÄ¸½Í¼¿ÉÖª£¬SARS-2 Sµ°°×µÚ444°±»ùËá¶ÔÓ¦SARS-1 Sµ°°×µÚ431°±»ùËá¡£

ͬÀí£¬Ìæ´úGlu354Asn£¨E354N£©±íʾ£¬Ïà¶ÔSARS-1£¬SARS-2 Sµ°°×µÄµÚ354°±»ùËáλµã·¢ÉúÁ˴ӹȰ±ËᣨE£¬Glu£©µ½Ì춬õ£°·£¨N£¬Asn£©µÄÌæ´ú»òÍ»±ä¡£SARS-2 Sµ°°×µÚ354°±»ùËá¶ÔÓ¦SARS-1 Sµ°°×µÚ341°±»ùËá¡£

ÓÉ¡°SARS-CoV-2 HS½áºÏÄÜÁ¦µÄÏÔÖøÌáÉý£¬ÊÇͨ¹ýÁ½¸ö°±»ùËáÌæ´úThr444LysºÍGlu354Asn»ñµÃµÄ¡±ÕâÒ»Åж¨¿ÉÖª£º

a)Èç¹ûSARS-1 Sµ°°×µÚ341°±»ùËáÓɹȰ±ËᣨE£¬Glu£©Í»±äΪÌ춬õ£°·£¨N£¬Asn£©£»Í¬Ê±£¬µÚ431°±»ùËáÓÉËÕ°±ËᣨT£¬Thr£©Í»±äΪÀµ°±ËᣨK£¬Lys£©£¬ÄÇô£¬SARS-1¾ÍÄÜÑÝ»¯³öÓëSARS-2Ïàͬ»òÏ൱µÄHS½áºÏÄÜÁ¦¡£

b)Èç¹ûÓÃÌ춬õ£°·£¨N£¬Asn£©Ìæ»»SARS-1 Sµ°°×µÚ341°±»ùËá¹È°±ËᣨE£¬Glu£©£»Í¬Ê±£¬ÓÃÀµ°±ËᣨK£¬Lys£©Ìæ»»µÚ431°±»ùËáËÕ°±ËᣨT£¬Thr£©£¬ÄÇô£¬¾Í»ùÓÚSARS-1¸ÄÔì³öÁËÒ»ÖÖHS½áºÏÄÜÁ¦ÓëSARS-2Ïàͬ»òÏ൱µÄÐÂÐ͹Ú×´²¡¶¾¡£

S0092-8674(20)31230-7_gr1_lrg_25p_D_E_F_marked.JPG

¶Ô½áºÏHS¹±Ï׸ߵÄSARS-2°±»ùËá²Ð»ù¼°¶ÔÓ¦µÄSARS-1°±»ùËá²Ð»ù

²»·ÁÔÙ˵Ã÷Ò»ÏÂÕâÁ½¸öÌæ´ú·¢ÏÖ¡¢È·ÈϵĹý³Ì£º

1£©Ñо¿ÕßÊ×ÏÈÕÒ³öÁ˶ԽáºÏHS¹±Ï׸ߣ¨°üÀ¨½Ó´¥Êý¹±Ï׺ÍÄÜÁ¿¹±Ï×£©µÄSARS-2°±»ùËá²Ð»ù£¬ÉÏͼÓúìÉ«·½¿ò±ê³öÁËÕâЩ²Ð»ù£¨E354N´¦ÒàÓ¦Óкì¿ò£©¡£
2£©½ÓÏÂÀ´±È½Ï¸ß¹±Ï×°±»ùËáÓëSARS-1ÖеĶÔӦλµã°±»ùËá¡£Ò»²¿·Ö¸ß¹±Ï×°±»ùËáÓëSARS-1ÖжÔӦλµã°±»ùËáÏàͬ£¬Ö»ÓÐËĸö¸ß¹±Ï×°±»ùËáÓëSARS-1ÖжÔӦλµã°±»ùË᲻ͬ£¬ËÄ×é²îÒì°±»ùËáÊÇK346R¡¢K357R¡¢E354N¡¢T444K¡£
3£©ËÄ×é²îÒì°±»ùËáÖеÄÇ°Á½×éK346R¡¢K357R¶¼ÊÇÀµ°±ËáKµ½¾«°±ËáRµÄ±£ÊØÌæ»»¡£Àµ°±Ëá¡¢¾«°±ËᶼÊǼîÐԲлù£¬¶þÕßÎïÀí¡¢»¯Ñ§ÐÔÖʽӽü£¬ËüÃÇÖ®¼äµÄÌæ»»¶ÔHS½áºÏÄÜÁ¦Ó°Ïì²»´ó¡£
4£©Òò´Ë£¬¶ÔSARS-2 HS½áºÏÄÜÁ¦ÌáÉýÆð¹Ø¼ü×÷ÓõÄÊÇÁíÍâÁ½×é²îÒì°±»ùËᣬ¼´Ìæ»»E354N¡¢T444K£¬Ò²¾ÍÊÇGlu354Asn¡¢Thr444Lys¡£

4¡¢SARS-2 RBDÔÚ¿ª·Å¹¹Ïó£¨RBD-Up£©ºÍ±ÕºÏ¹¹Ïó£¨RBD-Down£©Ï½ԿɽáºÏHS£¬ÔÚ¿ª·Å¹¹ÏóÏÂHS½áºÏÇ׺ÍÁ¦¸ü¸ß£»SARS-2 RBDÖ»ÄÜÔÚ¿ª·Å¹¹ÏóϽáºÏACE2¡£ÈçÏÂͼËùʾ£º


S0092-8674(20)31230-7_figs1_lrg_40p_top.JPG

SARS-2 RBDÔÚ¿ª·Å¹¹Ï󡢱պϹ¹ÏóϽԿɽáºÏHS£¬µ«Ö»ÄÜÔÚ¿ª·Å¹¹ÏóϽáºÏACE2

ͼÖÐÂÌÉ«²¿·Ö±íʾHS£¬×ÏÉ«²¿·Ö±íʾSARS-2 RBDÓëHSµÄÍƶ¨½áºÏÇøÓò¡£

5¡¢ACE2²»ÓëHS½áºÏ£¬ACE2²»Ó°ÏìSARS-2 SpikeÓëHSµÄ½áºÏ¡£

6¡¢SARS-2 Spike¿ÉÒÔ·Ö±ð½áºÏACE2ºÍHS£¬Ò²¿ÉÒÔͬʱÓë¶þÕß½áºÏ£¬²¢ÒÔ¸ÎËØΪ֧¼ÜÉú³ÉÈýÔª¸´ºÏÎRBDµÄHS½áºÏλµãÓëRBDµÄACE2½áºÏλµãÏàÁÚ¡£

7¡¢HSÌáÉýÁËS£¨Spike£©µ°°×µÄACE2½áºÏЧÂÊ¡£ÓëACE2½áºÏµÄSµ°°×ÊýÁ¿£¬Ëæ×ÅSµ°°×ÓëHSµÄ½áºÏ³É±ÈÀýµØÔö¼Ó£»µç×ÓÏÔ΢ÕÕƬ³ÉÏñÑо¿±íÃ÷£¬RBDÓëHSµÄ½áºÏ¿ÉÒÔÐγÉÓÐÀûÓÚ½áºÏACE2µÄ¿ª·Å¹¹Ï󣬿ÉÒÔÎȶ¨RBDÓëACE2µÄÏ໥×÷Óã¬Ôö¼ÓÓëACE2½áºÏµÄSpike±ÈÀý£¬²¢Ìá¸ßµ¥¸öSpike½áºÏACE2µÄÀûÓÃÂÊ£¨Ò»¸öSpikeÈý¾ÛÌå¿ÉÒÔ½áºÏ1~3¸öACE2£©¡£ÕâЩÇé¿ö±íÃ÷£¬HS×÷Ϊ¸¨ÖúÊÜÌåÆô¶¯¡¢´Ù½øÁËSARS-2 SpikeÓëACE2µÄÏ໥×÷ÓÃÓë½áºÏ¡£

8¡¢ÓøÎËØÁѽâøHSase£¨¿ÉÁѽ⡢½µ½âϸ°û±íÃæµÄHS£©Ô¤´¦Àíϸ°ûÅàÑøÎÏÔÖøÒÖÖÆÁËSARS-2 Spike¡¢RBDëÄÓëÁ½ÖÖÈËÀà·Îϸ°ûH1299¡¢A549£¬ÒÔ¼°ÓëÈËÀà¸Îϸ°ûHep3B¡¢ÈËÀàºÚÉ«ËØÁöϸ°ûA375µÄ½áºÏ¡£ÈçÏÂͼËùʾ£º

S0092-8674(20)31230-7_gr3_lrg_30p.JPG

HSaseÓÐÁ¦ÒÖÖÆÁËSARS-2 Spike¡¢RBDµÄ¶àÖÖϸ°û½áºÏÄÜÁ¦

H1299ϸ°û£ºÒ»ÖÖÔ´×Ô2ÐÍ·ÎÅÝϸ°ûµÄÈËÀà·ÎÏÙ°©£¨·ÇСϸ°û·Î°©£©Ï¸°ûϵ£¬ÓÐ˵H1299 ϸ°ûժȡ×ÔÁܰͽ᣻
A549ϸ°û£ºÁíÒ»ÖÖ2ÐÍÈËÀà·ÎÅÝÏÙ°©Ï¸°ûϵ£»
Hep3Bϸ°û£ºÒ»ÖÖÈ˸ΰ©Ï¸°ûϵ£»
A375ϸ°û£ºÒ»ÖÖÈ˶ñÐÔºÚÉ«ËØÁöϸ°ûϵ¡£

9¡¢ÓÃHSaseÔ¤´¦Àíϸ°ûÅàÑøÎ¼°Çóýϸ°ûÖеÄEXT1¡¢NDST1¡¢HS6ST1/2µÈºÏ³ÉHSËùÐèµÄÉúÎïºÏ³Éø»ùÒò¶¼·Ç³£ÏÔÖøµØÒÖÖÆÁËSARS-CoV-2 Spike¡¢RBDÓëHep3Bϸ°ûµÄ½áºÏ¡£ÈçÉÏͼF¼°ÏÂͼËùʾ£º

S0092-8674(20)31230-7_figs4.jpg

ʹÓÃHSase£¬ÇóýEXT1¡¢NDST1¡¢HS6ST1/2ÏÔÖøÒÖÖÆSARS-2 RBDµÄϸ°û½áºÏÄÜÁ¦

EXT1£ºExostosin-1£¬ÓëÁíÒ»»ùÒòEXT2±àÂëºÏ³ÉHSÖ÷Á´ËùÐèµÄÌÇ»ùתÒÆø£»
NDST1£ºN-Deacetylase And N-Sulfotransferase 1£¬N-ÍÑÒÒõ£Ã¸ºÍN-»Ç»ùתÒÆø1£¬Ò»ÖÖHSÖÐÐÄÐÞÊÎø£¨´ß»¯ÁòËáÑÎÓë̼ˮ»¯ºÏÎïµÄ½áºÏ£¬´ß»¯ÁòËáÑδÓ3'-Á×ËáÏÙÜÕ-5'-Á×ËáÁòËáÑÎתÒƵ½HSÖÐÆÏÌÑÌÇ°·µÄµª£©£»
HS6ST1/2£ºheparan sulfate 6-O-sulfotransferase1/2£¬ÁòËáÒÒõ£¸ÎËØ6-O-ÁòËáתÒÆø1/2£¬Á½ÖÖHSºÏ³ÉÐÞÊÎø£¨¹¦ÄÜÀàËÆNDST1£¬¿É½«ÏÙÜÕ3'-Á×Ëá-5'-Á×ËáÁòËáÖеÄÁòËáÑλùÍÅ´ß»¯×ªÒƵ½HSÖÐN-»Ç»ùÆÏÌÑÌÇ°·µÄµÚ6¸ö²Ð»ùλµã£©¡£

¡°-/-¡±±íʾÇóýÁËÏàÓ¦»ùÒò£¬ÀýÈ磬Hep3B EXT1-/-ÊÇÇóýÁËEXT1»ùÒòµÄHep3Bϸ°û¡£

10¡¢ÓÃÌáÈ¡×ÔÈËÀà·ÎÔà¡¢ÉöÔà¡¢¸ÎÔàºÍ±âÌÒÌåµÄHS£¨ÁòËáÒÒõ£¸ÎËØ£©Ô¤´¦Àíϸ°ûÅàÑøÎ¶¼ÏÔÖøÒÖÖÆÁËSARS-2 RBDÓëH1299ϸ°ûµÄ½áºÏ£¨ÏÂͼB¡£ÍâÔ´ÐÔHS½áºÏ¡¢ÏûºÄÁËSARS-2 RBD/Spike£¬±»ÍâÔ´ÐÔHSռλ½áºÏµÄRBD/Spike ²»ÄÜÔÙ½áºÏϸ°û±íÃæµÄHS£©£»ÓöàÖÖÍâÔ´ÐÔHeparin£¨¸ÎËØ£©/HSÔ¤´¦Àíϸ°ûÅàÑøÎ¶¼ÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëH1299ϸ°û£¨ÏÂͼC£©¡¢ÓëA549ϸ°û£¨ÏÂͼD£©µÄ½áºÏ¡£

S0092-8674(20)31230-7_gr4.jpg

ͼB£ºËÄÖÖÌáÈ¡À´Ô´µÄÍâÌí¼ÓHSÏÔÖøÒÖÖÆÁËSARS-2 RBDÓëH1299ϸ°ûµÄ½áºÏ£»
ͼC£ºCHO HS¡¢Heparin¡¢MST¡¢Split glycol HeparinÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëH1299ϸ°ûµÄ½áºÏ£»
ͼD£ºCHO HS¡¢Heparin¡¢MST¡¢Split glycol HeparinÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëA549ϸ°ûµÄ½áºÏ¡£

CHO HS£ºÌáÈ¡×ÔÖйú²ÖÊóÂѳ²µÄHS£¨ÁòËáÒÒõ£¸ÎËØ£©¡£CHO£ºChinese hamster ovary£¬Öйú²ÖÊóÂѳ²£»
Heparin£º¸ÎËØ£»
MST£ºÖ¸MST heparin£¬ÌáÈ¡×ÔMST£¨murine mastocytoma£¬Ð¡Êó·Ê´óϸ°ûÁö£©Ï¸°ûµÄ¸ÎËØ£»
Split glycol Heparin£ºÁѽâÒÒ¶þ´¼¸ÎËØ/ÒÒ¶þ´¼Áѽâ¸ÎËØ¡£

11¡¢ACE2¹ý±í´ï£¨Í¨¹ýACE2»ùÒòתȾ£©ÏÔÖøÌáÉýÁËSARS-2 SpikeÓëA375ϸ°ûµÄ½áºÏ£¨ÏÂͼB£©£»
ÓøÎËØÁѽâøHSaseÔ¤´¦Àíϸ°ûÅàÑøÎï¡¢Çóýϸ°ûÖеÄÌÇ°·¾ÛÌÇ×é×°»ùÒòB4GALT7ÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëA375ϸ°ûµÄ½áºÏ£¨ÏÂͼB£©£»
ÇóýACE2ÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëA549ϸ°ûµÄ½áºÏ£¨ÏÂͼC£©£»
ÓøÎËØÁѽâøHSaseÔ¤´¦Àíϸ°ûÅàÑøÎïÏÔÖøÒÖÖÆÁËSARS-2 SpikeÓëA549ϸ°ûµÄ½áºÏ£¨ÏÂͼC£©£»
ÕâЩ½á¹û±íÃ÷£¬SARS-2 SpikeÓëϸ°ûµÄ½áºÏͬʱÒÀÀµÓÚACE2ºÍHS¡£

S0092-8674(20)31230-7_gr5.jpg

A375 B4GALT7-/-ÊÇÇóýÁËB4GALT7»ùÒòµÄA375ϸ°û£»

A549 ACE2-/-C3¡¢A549 ACE2-/-C6ÊÇÁ½×éÇóýÁËACE2»ùÒòµÄA549ϸ°û£¬²»Çå³þ¶þÕßµÄÇø±ð¡£

12¡¢SARS-CoV-2¼Ù²¡¶¾¸ÐȾҲÒÀÀµÓÚHS£¨Ö®Ç°ÊµÑéΪµ°°×-µ°°×¡¢µ°°×-ϸ°û½áºÏʵÑ飬²»ÊǸÐȾʵÑé¡£¸ÐȾÊǽøÈëϸ°û£¬Óëϸ°û½áºÏ£¬¼´Óëϸ°ûĤ±íÃæµÄÊÜÌå½áºÏÖ»ÊǸÐȾµÄÇ°×ࣩ£¬Ê¹ÓÃHSaseÔ¤´¦Àí£¬Ê¹ÓÃÍâÔ´ÐÔHS/heparinÔ¤´¦Àí£¬ÇóýEXT1¡¢NDST1¡¢HS6ST1/2¶¼ÓÐЧÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾¶ÔVero E6ϸ°û£¨·ÇÖÞÂ̺ïÉöϸ°ûϵϸ°û£©µÄ¸ÐȾ¡£ÈçÏÂͼËùʾ£º

S0092-8674(20)31230-7_gr6.jpg

SARS-COV-2¼Ù²¡¶¾¶ÔVero E6ϸ°ûµÄ¸ÐȾÒÀÀµÓÚHS

SARS-CoV-2¼Ù²¡¶¾ÊÇÓÃSARS-CoV-2 Spikeµ°°×Ìæ´úVSV£¨vesicular stomatitis virus£¬Ë®ÅÝÐÔ¿ÚÑײ¡¶¾£©µÄGµ°°×»ñµÃµÄ£»

13¡¢ÈçÉÏͼHËùʾ£¬HSase£¨¸ÎËØÁѽâø£©ÏÔÖøÒÖÖÆÁËSARS-CoV-2¸ÐȾ£¬µ«Ïà±È֮ϣ¬HSase·´¶øÏÔÖøÌáÉýÁËSARS-CoV-1¸ÐȾ£»Óë´Ëͬʱ£¬HSase¶ÔMERS-CoV¸ÐȾҲȱ·¦ÒÖÖÆ×÷Óã¬ÈçÏÂͼËùʾ£º

S0092-8674(20)31230-7_figs6_lrg_70p.PNG

HSase²»ÒÖÖÆMERS-CoV¼Ù²¡¶¾¶ÔHep3Bϸ°ûµÄ¸ÐȾ

¿É¼û£¬HS¶ÔSARS-COV-2¸ÐȾµÄ´Ù½ø¾ßÓÐÒ»¶¨ÌØÒìÐÔ£»Ï¸°ûĤ±íÃæµÄHS²»ÊÇSARS-CoV-1ºÍMERS-CoVµÄ¸ÐȾ´Ù½øÒò×Ó£»HS¿ÉÄܸÉÈÅ¡¢ÒÖÖÆSARS-CoV-1µÄÊÜÌå½áºÏºÍϸ°û½øÈë¡£

14¡¢HSÒ²ÊÇSARS-COV-2Õ没¶¾ÓÐЧ¸ÐȾËùÐèÒªµÄ¡£
HSase¡¢UFHÔ¤´¦ÀíÏÔÖøÒÖÖÆÁËSARS-COV-2Õ没¶¾¶ÔVero E6ϸ°ûµÄ¸ÐȾ£¨ÏÂͼB¡¢C£©£»
ÇóýNDST1ÍêÈ«ÒÖÖÆ£¨Ïû³ý£©¡¢ÇóýHS6ST1/2ÏÔÖøÒÖÖÆÁËSARS-COV-2Õ没¶¾¶ÔHep3Bϸ°ûµÄ¸ÐȾ£¨ÏÂͼD£©£»
HSase¡¢UFHÔ¤´¦Àí»¹ÏÔÖø£¨5±¶ÒÔÉÏ£©ÒÖÖÆÁËSARS-COV-2Õ没¶¾¶ÔÔ­´úÈËÖ§Æø¹ÜÉÏƤϸ°û£¨primary human bronchial epithelial cells£©µÄ¸ÐȾ£¨ÏÂͼF¡¢G£©¡£

S0092-8674(20)31230-7_gr7.jpg

UFH£ºunfractionated heparin£¬Î´Áѽâ¸ÎËØ£¬Ò²½ÐÆÕͨ¸ÎËØ£¬ÓëUFHÏà¶ÔµÄÊǵͷÖ×ÓÁ¿¸ÎËØ¡£

ÂÛÎÄÒÀ¾Ý¶þ

Infection and transmission of SARS©CoV©2 depend on heparan sulfate proteoglycans
SARS-CoV-2µÄ¸ÐȾºÍ´«²¥ÒÀÀµÓÚÁòËáÒÒõ£¸ÎËص°°×¾ÛÌÇ
https://www.embopress.org/doi/full/10.15252/embj.2020106765

ÂÛÎÄÒªµãÈçÏ£º

1¡¢È·¶¨ÁËÁòËáÒÒõ£¸ÎËص°°×¾ÛÌÇ£¨HSPG£©ÊÇSARS-CoV-2µÄ¸½×ÅÊÜÌ壬ÇÒÊÇACE2ÊÜÌåµÄ¹²ÊÜÌå¡£

2¡¢UF heparin¡¢anti-ACE2¡¢¼°´ÓCOVID-19»¼ÕßÖзÖÀë³öµÄÈýÖÖSARS-CoV-2ÖкͿ¹Ì嶼¿É¸ÉÈŲ¢ÏÔÖøÒÖÖÆSARS-CoV-2¼Ù²¡¶¾ÓëÈËÀà¸ÎÔàHuh7.5ϸ°ûµÄ½áºÏ£¨Í¼A£©£»
ÓÃheparinase IIIÈ¥³ýϸ°ûÖеÄHSÏÔÖøÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾ÓëHuh7.5ϸ°ûµÄ½áºÏ£¨Í¼B£©£»
ÇóýExostosin-1£¨EXT1£©»ùÒò¼°Ê¹ÓÃUF heparin¼«´óÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾ÓëHuh7.5ϸ°ûµÄ½áºÏ£¨Í¼D£©¡£

embj2020106765-fig-0001-m_30p.JPG


UF heparin£¬¾ÍÊÇUnfractionated heparin£¨UFH£©£¬Î´Áѽâ¸ÎËØ»òÆÕͨ¸ÎËØ¡£ÈçÇ°ËùÊö£¬heparin¿É½áºÏ¡¢ÏûºÄSARS-2µÄSµ°°×£¬¸ÉÈÅ¡¢ÒÖÖÆÆäÓëϸ°û±íÃæHS/HSPGÊÜÌåµÄ½áºÏ¡£

anti-ACE2£¬ACE2ÖкͿ¹Ì壻

ÈýÖÖSARS-CoV-2ÖкͿ¹ÌåÊÇÁ½ÖÖRBDÖкͿ¹ÌåCOVA1-18¡¢COVA2-15£¬¼°Ò»ÖÖ·ÇRBDÖкͿ¹ÌåCOVA1-21£»

heparinase III£¬¸ÎËØø¢ó£¬Ò»ÖÖ¶àÌÇÁѽâø£¬¿ÉÇи½µ½âHS£»

SARS-CoV-2¼Ù²¡¶¾ÊÇÓÃSARS-CoV-2 Sµ°°×ÓëÈ¥²¡¶¾ÐÔHIV-1¹Ç¼ÜǶºÏÖÆ×÷µÄ£»

Huh7ÊÇÒ»ÖÖÈËÀà¸Î°©Ï¸°ûϵ£¬Huh7.5 ÊÇHuh7µÄÑÜÉúϸ°ûϵ£»

ÈçÇ°ËùÊö£¬Exostosin-1£¨EXT1£©ÊǺϳÉHSÖ÷Á´ËùÐèµÄÒ»ÖÖÌÇ»ùתÒÆø»ùÒò£»

XG1/XG-1ÊÇÒ»ÖÖÈ˶෢ÐÔ¹ÇËèÁöϸ°û£¬XG1-EXT1−/−ÊÇÇóýÁËExostosin-1£¨EXT1£©»ùÒòµÄXG1ϸ°û¡£

3¡¢ÓÃËÄÖÖ£¨ÍâÔ´ÐÔÌí¼ÓµÄ£©LMWH£¨µÍ·Ö×ÓÁ¿¸ÎËØ£©Ô¤´¦Àíϸ°ûÅàÑøÎïÏÔÖøÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾¶ÔHuh7.5ϸ°ûµÄ½áºÏ¡¢¸ÐȾ£¬ËüÃǵÄÒÖÖÆЧ¹ûÓëUF heparin£¨ÆÕͨ¸ÎËØ£©Ï൱£¨ÏÂͼA¡¢Í¼B¡¢Í¼C£©¡£

embj2020106765-fig-0002-m_30p.JPG

ͼA£ºUF heparin¡¢enoxaparinÒÖÖÆSARS-2¼Ù²¡¶¾¶ÔHuh7.5ϸ°ûµÄ¸ÐȾ£¬ÒÖÖƳ̶ÈÓëŨ¶ÈÕýÏà¹Ø£»
ͼB£ºUF heparin¡¢ËÄÖÖLMWHÏÔÖøÒÖÖÆSARS-2¼Ù²¡¶¾ÓëHuh7.5ϸ°ûµÄ½áºÏ£»
ͼC£ºUF heparin¡¢ËÄÖÖLMWHÏÔÖøÒÖÖÆSARS-2¼Ù²¡¶¾¶ÔHuh7.5ϸ°ûµÄ¸ÐȾ£»
ͼD£ºUF heparin¡¢enoxaparin¡¢anti-ACE2¼«´óÒÖÖÆÁËSARS-COV-2¼Ù²¡¶¾¶Ô293T-ACE2ϸ°ûµÄ¸ÐȾ£»
ͼE£ºËµÃ÷ÂÔ¡£

LMWH£¬low molecular weight heparins£¬µÍ·Ö×ÓÁ¿¸ÎËØ£¬ÊÇÆÕͨ¸ÎËصÄÈ˹¤Áѽâ²úÎï¡£LMWH¡¢UF heparin£¨UFH£¬Î´Áѽâ¸ÎËØ¡¢ÆÕͨ¸ÎËØ£©Êdz£ÓõĿ¹ÄýѪµ°°×£¨¿¹ÄýѪ¼Á/¿¹ÑªË¨¼Á£©¡£Õâ¶þÀà¸ÎËØÔÚ±¾ÂÛÎÄÖж¼ÓÃ×÷HS/HSPG¸ÉÈÅ¡¢ÒÖÖƼÁ¡£

¸ÃÑо¿Ê¹ÓÃÁËËÄÖÖLMWH£ºtinzaparin¡¢dalteparin ¡¢enoxaparin¡¢nadroparin£¬ÆäÖÐÓÅÏÈʹÓõÄÊÇenoxaparin¡£

4¡¢ACE2¿¹ÌåÏÔÖøÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾ÓëHuh7.5ϸ°ûµÄ½áºÏ£¨ÈçÇ°ÃæÒªµã2ϵĸ½Í¼AËùʾ£©£»
ACE2¿¹Ìå¡¢UF heparin¡¢enoxaparin¶¼¼«´óÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾¶Ô293T-ACE2ϸ°ûµÄ¸ÐȾ£¨ÉÏͼD£©¡£
ÕâÁ½×é½á¹û±íÃ÷£¬ACE2½éµ¼µÄSARS-CoV-2¸ÐȾÐèÒªHS/HSPG£¬¶øHS/HSPG²ÎÓëµÄSARS-CoV-2¸ÐȾҲÐèÒªACE2£¬Òò´Ë£¬HS/HSPGÔÚSARS-CoV-2¸ÐȾÖÐÊÇACE2µÄ¹²ÊÜÌå¡£

293Tϸ°û¼´HEK293Tϸ°û£¬ÊÇHEK293£¨Human Embryonic Kidney Cells 293£¬ÈËÅßÌ¥Éöϸ°û293£©µÄÑÜÉúϸ°ûϵ¡£293T-ACE2ϸ°ûÊÇתȾ¹ý±í´ïACE2µÄ293Tϸ°û£¬293Tϸ°û×ÔÉíÓ¦¸Ã²»±í´ï»ò¼«ÉÙ±í´ïACE2¡£

5¡¢UF heparinºÍLMWH£¨enoxaparin£©ÓÐЧÒÖÖÆÁËSARS-COV-2¼Ù²¡¶¾¡¢Õ没¶¾¶ÔÁ½ÖÖ¼«»¯×´Ì¬µÄÉÏƤϸ°ûCaco-2£¨ÏÂͼC£©ºÍCalu-3£¨ÏÂͼD£©µÄ¸ÐȾ¡£

embj2020106765-fig-0003-m_30p.JPG

UF heparin¡¢LMWHÒÖÖÆSARS-2¼Ù²¡¶¾¶Ô¼«»¯µÄÉÏƤϸ°ûCaco-2¡¢Calu-3µÄ¸ÐȾ

ͼC£ºUF heparin¡¢enoxaparin¡¢anti-ACE2ÒÖÖÆSARS-2¼Ù²¡¶¾ÓëCaco-2ϸ°ûµÄ½áºÏ£»
ͼD£ºUF heparin¡¢enoxaparin¡¢anti-ACE2ÒÖÖÆSARS-2¼Ù²¡¶¾ÓëCalu-3ϸ°ûµÄ½áºÏ£»
ͼE¡¢Í¼F£ºenoxaparin¡¢anti-ACE2ÒÖÖÆSARS-CoV-2Õ没¶¾¶ÔCalu-3ϸ°ûµÄ¸ÐȾ¡£
ͼE¶ÔÓ¦£¨PCR²âµÃµÄ£©³É¹¦¸ÐȾµÄSARS-CoV-2Ïà¶Ô¼ÆÊý£»Í¼F¶ÔÓ¦£¨PCR²âµÃµÄ£©¸ÐȾºó¸´ÖƲúÉú²¢·ÖÃÚµ½ÉÏÇåÒº£¨supernatant£©ÖеÄSARS-CoV-2Ïà¶Ô¼ÆÊý¡£

Caco-2ÊÇÒ»ÖÖ½áÖ±³¦ÏÙ°©Ï¸°ûϵ£»
Calu-3ÊÇÒ»ÖÖÖ§Æø¹ÜÏÙ°©Ï¸°ûϵ£»

SARS-CoV-2 isolateÊÇÒ»¸ö·ÖÀë×ÔItalyµÄ¶¾Öê¡£

±ÊÕ߶Լ«»¯µÄϸ°ûÈÏʶǷÇåÎú¡¢È·ÇС£Ï¸°ûÔÚ°²¾²£¨Î´Êܴ̼¤£©Ê±£¬Ï¸°ûĤÁ½²àÍâÕýÄÚ¸ºµÄ´øµç״̬³ÆΪĤµÄ¼«»¯×´Ì¬£¬¼«»¯µÄϸ°û¿ÉÄÜָϸ°ûĤ´¦ÓÚ¼«»¯×´Ì¬µÄ£¬´øµç״̬ÍâÕýÄÚ¸ºµÄϸ°û£¬»òĤÄÚÍâµçλ´ïµ½Ä³Ò»ÊýÖµµÄϸ°û¡£´ó¶àÊý¸ßµÈÉúÎïÌåÔÚδÊܴ̼¤Ê±Î¬³Ö´ø¸ºµçµÄÄÚ²¿»·¾³¡£HS/HSPGµÄ¾ÛÌÇÁ´´ø¸ß¸ºµçºÉ£¬¼«»¯µÄϸ°ûÍⲿ´øÕýµçºÉ£¬¶þÕßÈÝÒ×Ï໥ÎüÒý¡¢½áºÏ¡£ÉÏͼBÏÔʾ£¬¼«»¯×´Ì¬µÄCaco-2¡¢Calu-3ϸ°ûµÄACE2±í´ïÔ¶¸ßÓڷǼ«»¯×´Ì¬µÄCaco-2¡¢Calu-3ϸ°û£¬²»Çå³þÔì³ÉÕâÖÖÍ»³ö²îÒìµÄÔ­Òò¡£

6¡¢HSPG¶ÔSARS-CoV-2µÄϸ°û½áºÏºÜÖØÒª¡£Á½ÖÖHSPG Syndecan 1»òSyndecan 4µÄתȾ±í´ïÏÔÖøÌáÉýÁËSARS-CoV-2¼Ù²¡¶¾¡¢Õ没¶¾ÓëNamalwaϸ°ûµÄ½áºÏ£»ÍâÔ´ÐÔUF heparinºÍLMWH£¨enoxaparin£©¾ùÏÔÖøÒÖÖÆÁËSARS-CoV-2¼Ù²¡¶¾¡¢Õ没¶¾ÓëNamalwaϸ°ûµÄ½áºÏ¡£ÈçÏÂͼËùʾ£º

embj2020106765-fig-0004-m_30p.JPG

ͼA£ºSyndecan 1»òSyndecan 4µÄתȾ±í´ïÏÔÖøÌáÉýÁËSARS-2¼Ù²¡¶¾ÓëNamalwaϸ°ûµÄ½áºÏ£»UF heparin¡¢enoxaparinÏÔÖøÒÖÖÆÁËSARS-2¼Ù²¡¶¾ÓëNamalwaϸ°ûµÄ½áºÏ¡£
ͼB£ºSyndecan 1»òSyndecan 4µÄתȾ±í´ïÏÔÖøÌáÉýÁËSARS-2Õ没¶¾ÓëNamalwaϸ°ûµÄ½áºÏ£»enoxaparinÏÔÖøÒÖÖÆÁËSARS-2Õ没¶¾ÓëNamalwaϸ°ûµÄ½áºÏ¡£

NamalwaÊÇÒ»ÖÖÈËÁÜ°ÍÁöϸ°ûϵ£¬Namalwaϸ°û±¾Éí¼È²»±í´ïHS/HSPG£¬Ò²²»±í´ïACE2¡£SARS-2¿É½áºÏתȾ±í´ïHSPGµÄNamalwaϸ°û£¨Óëϸ°û±íÃæµÄHSPG½áºÏ£©£¬µ«Î´Ôì³É¸ÐȾ£¨Î´½øÈëϸ°û£©¡£

7¡¢ÈýÖÖSARS-CoV-2ÖкͿ¹ÌåCOVA1-18¡¢COVA2-15¡¢COVA1-21ÓÐЧÒÖÖÆÁËSARS-CoV-2ÓëתȾ±í´ïSyndecan 1µÄNamalwaϸ°ûµÄ½áºÏ£¬ÈýÖÖ¿¹ÌåµÄÒÖÖÆЧ¹ûÓëenoxaparinÏ൱¡£Ò»Ð©SARS-CoV-2µÄ·ÇÖкͿ¹ÌåûÓÐÏàÓ¦µÄÒÖÖÆ×÷Óá£ÈçÏÂͼËùʾ£º

embj2020106765-fig-0005-m_30p.JPG


ͼA£ºCOVA1-18¡¢COVA2-15¡¢COVA1-21¡¢enoxaparinÓÐЧÒÖÖÆÁËSARS-2¼Ù²¡¶¾ÓëSyndecan 1-Namalwaϸ°ûµÄ½áºÏ£»
ͼB£ºCOVA1-18¡¢COVA2-15¡¢COVA1-21¡¢enoxaparinÓÐЧÒÖÖÆÁËSARS-2Õ没¶¾ÓëSyndecan 1-Namalwaϸ°ûµÄ½áºÏ¡£

ÕâЩ½á¹ûÔٴαíÃ÷£¬SARS-2ͨ¹ýSµ°°×½áºÏHSPG£¬´Ó¶øÓëϸ°û½áºÏ¡£

±ÊÕß×¢£ºÈýÖÖSARS-2ÖкͿ¹ÌåµÄSARS-2-S RBD½áºÏλµã£¬ÓëSyndecan 1»òHSPGµÄSARS-2-S RBD½áºÏλµãÓ¦¸Ã´æÔÚÖغϡ¢¾ºÕù¡£

8¡¢²»±í´ïACE2µÄÊ÷ͻ״ϸ°û£¨DC£¬Dendritic Cells£©ºÍƤ·ôճĤÀʸñººË¹Ï¸°û£¨LC£¬Langerhans cells£¬DCϸ°ûµÄÒ»¸ö×ÓÀࣩ²»»á±»SARS-CoV-2¸ÐȾ£¬µ«ÕâÁ½¸öDCÑÇȺ¿Éͨ¹ýHSPG£¨ÁòËáÒÒõ£¸ÎËص°°×¾ÛÌÇ£©ÓÐЧ½áºÏ¡¢²¶»ñSARS-CoV-2£¬²¢½«²¡¶¾´«²¥¸ø±í´ïACE2µÄÈ˸ÎÔàHuh7.5ϸ°û£¬²¢µ¼ÖÂHuh7.5ϸ°û±»¸ÐȾ¡£Õ⣨Я´øSARS-2µÄDCϸ°ûµÄǨÒÆ£©Ò²¿ÉÄÜÊÇSARS-CoV-2´ÓºôÎüµÀճĤµ½´ï¡¢¸ÐȾÁÜ°Í×éÖ¯µÄ´«²¥Í¾¾¶¡£

embj2020106765-fig-0006-m_60p_E.JPG

ACE2ÒõÐÔµÄDCϸ°û½áºÏ¡¢Ð¯´øSARS-2²¢Ôì³ÉACE2ÑôÐÔµÄHuh7.5±»¸ÐȾ

SARS-CoV-2µÄÉÏÊö´«²¥·½Ê½ÓëDCϸ°ûÌåÄÚ´«²¥HIV-1ÏàËÆ¡£

9¡¢LMWH£¨enoxaparin£©¿É·ÀÖ¹DCϸ°ûÑÇȺÌåÄÚ´«²¥SARS-CoV-2¡£

10¡¢SARS-CoV-2Õ没¶¾¿É½áºÏ¡¢¸ÐȾԭ´ú±Çϸ°û£¨primary nasal cells£©£¬Ê¹ÓÃenoxaparin¿ÉÏÔÖøÒÖÖƽáºÏÓë¸ÐȾ£¬Õâ±íÃ÷HSPG²ÎÓëSARS-2¶ÔÔ­´ú±Çϸ°ûµÄ¸ÐȾ¡£

embj2020106765-fig-0007-m_30p.JPG

ͼB£ºÔ­´ú±Çϸ°û¸ß±í´ïÁ½ÖÖHSPG£¬Í¬Ê±ÓÐÉÙÁ¿ACE2±í´ï£»
ͼC£ºSARS-2¿É½áºÏÔ­´ú±Çϸ°û£¬enoxaparin¡¢anti-ACE2²»Í¬³Ì¶ÈÒÖÖƶþÕߵĽáºÏ£»
ͼD£ºSARS-2¿É¸ÐȾԭ´ú±Çϸ°û£¬enoxaparin¡¢anti-ACE2²»Í¬³Ì¶ÈÒÖÖÆSARS-2¶ÔÔ­´ú±Çϸ°ûµÄ¸ÐȾ¡£


ÂÛÎÄÒÀ¾ÝÈý

Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer
ÁòËáÒÒõ£¸ÎËشٽø´ÌÍ»µ°°×½éµ¼µÄSARS-CoV-2ËÞÖ÷ϸ°ûÇÖÏ®£¬²¢Ôö¼ÓÁËSARS-CoV-2 G614Í»±äÌåºÍ·Î°©£¨»¼Õߣ©µÄ¸ÐȾ
https://www.frontiersin.org/articles/10.3389/fmolb.2021.649575/full

ÂÛÎÄÖ¸³ö£º

1¡¢ÁòËáÒÒõ£¸ÎËØ£¨HS£©¿ÉÒÔ½áºÏSARS-CoV-2´ÌÍ»µ°°×£¨Sµ°°×£©£¬²¢ÔÚϸ°û±íÃæÓëACE2Эͬ½éµ¼SARS-CoV-2¶ÔËÞÖ÷ϸ°ûµÄ¸ÐȾ£»

2¡¢ËÞÖ÷ϸ°û±íÃ棨Ӧָϸ°ûĤ£©ÓëSARS-2-SµÄ½áºÏÈ¡¾öÓÚËÞÖ÷ϸ°û±íÃæµÄHS±í´ï£¬ÕâÖÖ½áºÏÊÇSARS-CoV-2¸ÐȾËÞÖ÷ϸ°ûËù±ØÐèµÄ£»

3¡¢SARS-CoV-2 Sµ°°×Óëϸ°ûµÄ½áºÏ¿ÉÒÔ±»¸ÎËØÁѽâøHSase¡¢HSÞ׿¹¼Ásurfen¡¢¸ÎËØ£¨heparin£¬HP£©ºÍ¶àÖÖ¸ÎËØÑÜÉúÎï×è¶Ï£»

4¡¢¸ÎËØ/HSÓëSARS-2-SµÄ½áºÏÖ÷ÒªÓÉËüÃǵÄÕûÌåÁòËữ¾ö¶¨£¬Ìض¨SARS-2-S½áºÏ»ùÐò¶Ô½áºÏµÄDZÔÚ¹±Ï×½ÏС£»

5¡¢SARS-2-S G614Í»±äÌåÓë¸ÎËصĽϸ߽áºÏÇ׺ÍÁ¦ºÍÉϵ÷µÄHS±í´ï£¬¿ÉÄÜÊÇSARS-CoV-2 G614Í»±äÌå¾ßÓнϸߴ«È¾ÐÔ£¬ºÍ·Î°©»¼Õ߶ÔSARS-CoV-2¸ÐȾ¸ß¶ÈÒ׸еIJ¿·ÖÔ­Òò£»

6¡¢SARS-CoV-2 G614±äÌå¼Ù²¡¶¾¶ÔËÞÖ÷ϸ°ûµÄ½Ï¸ß¸ÐȾÒÔ¼°HS±í´ïÉϵ÷ÒýÆðµÄ¸ÐȾÔöÇ¿¿É±»¸ÎËØÁѽâøHSaseºÍ¸ÎËØÓÐЧ×è¶Ï£¬Ò²¿ÉÄܱ»surfenºÍ¸ÎËØÑÜÉúÎï×è¶Ï£»

7¡¢ÎÒÃǵÄÑо¿½á¹ûÖ§³Ö£¬×è¶ÏHSÓëSARS-2-SµÄÏ໥×÷ÓÿÉÄÜÓÐÖúÓÚCOVID-19µÄÔ¤·ÀºÍÖÎÁÆ¡£

SARS-CoV-2 G614Í»±äÌå¼´D614GÍ»±äÌ壬ÆäSµ°°×µÚ614°±»ùËáÓÉÌ춬°±ËáDÍ»±äΪ¸Ê°±ËáG¡£G614Í»±äÌå¸ÐȾÄÜÁ¦¸üÇ¿£¬´«²¥¸ü¿ì£¬Æä¸ÐȾµÎ¶ÈÏà±ÈD614¶¾ÖêÔö¼Ó2.6ÖÁ9.3±¶¡£G614Í»±äÌå2020Äê1Ôµ×ÔÚÖйúºÍµÂ¹úÊÕ¼¯µÄ²¡¶¾ÖпªÊ¼±»¼ì²âµ½£¬2020Äê5ÔÂÇ°ºó£¬G614Í»±äÌå³ÉΪȫÇòÖ÷µ¼ÐÔµÄSARS-CoV-2 ¶¾Öê¡£

ÆäËüÂÛÎÄÒÀ¾Ý»òÏà¹ØÂÛÎÄ

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
ÁòËáÒÒõ£¸ÎËØЭÖúSARS-CoV-2½øÈëϸ°û£¬²¢¿É±»Åú×¼µÄÌåÍâÒ©Îï°ÐÏò
https://www.nature.com/articles/s41421-020-00222-5

Host and viral determinants for efficient SARS-CoV-2 infection of the human lung
SARS-CoV-2ÓÐЧ¸ÐȾÈ˷εÄËÞÖ÷ºÍ²¡¶¾¾ö¶¨ÒòËØ
https://www.nature.com/articles/s41467-020-20457-w

Heparan Sulfate Proteoglycans in Viral Infection and Treatment: A Special Focus on SARS-CoV-2
²¡¶¾¸ÐȾºÍÖÎÁÆÖеÄÁòËáÒÒõ£¸ÎËص°°×¶àÌÇ£¨HSPGs£©£º¶ÔSARS-CoV-2µÄÌرð¹Ø×¢
https://www.mdpi.com/1422-0067/22/12/6574

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
¸ÎËغÍÑÏÖؼ±ÐÔºôÎü×ÛºÏÕ÷Ïà¹Ø¹Ú×´²¡¶¾2(SARS-CoV-2)´ÌÍ»Ìǵ°°×½áºÏÏ໥×÷ÓõıíÕ÷
https://pubmed.ncbi.nlm.nih.gov/32653452/


6¡¢Vimentin£¨VIM£©


Vimentin£¨VIM£©£¬²¨Ðε°°×£¬Ò²½Ð²¨ÐÎÏËάµ°°×£¬ÊÇÒ»ÖÖIIIÐÍÖмäË¿µ°°×ÖÊ£¨Intermediate Filament Protein£©¡£

ÖмäË¿µ°°×ÊÇÕæºËÉúÎïϸ°ûµÄÖØÒª½á¹¹µ°°×£¬ÖмäË¿µ°°×¡¢Î¢¹Üµ°°×¡¢¼¡¶¯µ°°×΢ϸ˿£¬ÈýÕߺϳÆϸ°û¹Ç¼Ü£¨µ°°×£©¡£

²¨Ðε°°×ÊǼäÖÊϸ°û¹Ç¼ÜµÄÖ÷Òª×é³É²¿·Ö¡£²¨Ðε°°×ΧÈÆϸ°ûºË²¢¿çԽϸ°ûÍâΧ£¬ÔÚϸ°ûÄÚÐγɶ¯Ì¬ÇÒÁé»îµÄÍøÂ磬ά³Öϸ°ûµÄ½á¹¹¡¢ÐÎ̬¡¢ÍêÕûÐÔ£¬²¢ÔÚ¶àÖÖϸ°ûʼþÖз¢»ÓÖØÒª×÷Óá£

799px-Protein_VIM_PDB_1gk4_2.PNG

²¨Ðε°°×£¨Vimentin£©ÐÎ̬ʾÒâͼ

Vimentin£¨VIM£©ÊÇϸ°û·Ö»¯¹ý³ÌÖÐ×îÏȱí´ïµÄµ°°×¡£VIMÔÚ³ÉÏËάϸ°û£¨½áµÞ×éÖ¯ÖÐ×î³£¼ûµÄϸ°û£©¡¢ÄÚƤϸ°û¡¢Æ½»¬¼¡Ï¸°û¡¢ºÚÉ«ËØϸ°û¡¢Ñ©Íúϸ°û£¨Schwann cell£¬Éñ¾­½ºÖÊϸ°û¡¢Éñ¾­Ä¤Ï¸°û£©¡¢¶àÖÖÃâÒßϵͳϸ°û£¨¾ÞÊÉϸ°û¡¢µ¥ºËϸ°û¡¢Á£Ï¸°ûÒÔ¼°TºÍBÁÜ°Íϸ°û£©µÈµÈ¼ä³äÖÊÀ´Ô´µÄϸ°û¼°Èí×éÖ¯Öй㷺±í´ï£¬VimentinÒ²ÔÚ·ÎÅÝIIÐÍϸ°ûºÍ±Ç±­×´·ÖÃÚϸ°ûÖбí´ï£¬vimentin»¹ÔÚ¶àÖÖÖ×Áö×éÖ¯Öи߱í´ï£¬²¢ÓëÖ×ÁöµÄ·¢Éú¡¢·¢Õ¹ºÍÇÖϮתÒÆÃÜÇÐÏà¹Ø¡£

²¨Ðε°°×£¨Vimentin£¬VIM£©Ö÷ҪλÓÚϸ°ûÖÊÖУ¬ËüÒ²³öÏÖÔÚϸ°ûĤ±íÃæºÍϸ°ûÍâ½éÖÊÖУ¬ÔÚһЩϸ°û£¨ÈçIIÐÍ·ÎÅÝϸ°ûºÍ±ÇÇ»·ÖÃÚϸ°û£©±íÃ棬²¨Ðε°°×Óкܸߵıí´ï¡£

ϸ°û±íÃæµÄ²¨Ðε°°×ÊǶàÖÖ²¡¾ú¡¢²¡¶¾¸ÐȾϸ°ûËùÐèµÄÊÜÌå¡¢¹²ÊÜÌå»ò¸½×ÅÒò×Ó£¬ÕâЩ²¡Ô­Ìå°üÀ¨Escherichia coli K1£¨´ó³¦¸Ë¾úK1£¬ÐÂÉú¶ùÄÔĤÑ׵IJ¡Ô­Ì壩¡¢Streptococcus pyogenes£¨»¯Å§ÐÔÁ´Çò¾ú£©¡¢enterovirus 71£¨³¦µÀ²¡¶¾71ÐÍ£©¡¢dengue virus£¨µÇ¸ïÈȲ¡¶¾£©¡¢cowpea mosaic virus£¨ôø¶¹»¨Ò¶²¡¶¾£¬Ò»ÖÖÖ²Îﲡ¶¾£©¡¢Japanese encephalitis virus £¨ÈÕ±¾ÄÔÑײ¡¶¾£©¡¢human papillomavirus£¨HPV£¬ÈËÈéÍ·Áö²¡¶¾£¬¼âÈñʪðàµÄ²¡Ô­Ì壩¡¢SARS-CoVµÈ£¬ÆäÖУ¬vimentinÊÇSARS-CoV-1µÄÖ÷ÒªÊÜÌåACE2µÄ¹²ÊÜÌ壨¸¨ÖúÊÜÌ壩¡£

ÀàËÆSARS-CoV-1£¬vimentinÒ²ÊÇSARS-CoV-2µÄÖØÒªÊÜÌåACE2µÄ¹²ÊÜÌ壨¸¨ÖúÊÜÌ壩¡£

ÂÛÎÄÒÀ¾ÝÒ»

Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells
²¨Ðε°°×ÊÇSARS-CoV-2ÔÚÉÏƤϸ°ûÖеÄÒ»ÖÖÖØÒªACE2¹²ÊÜÌå
https://www.cell.com/iscience/fulltext/S2589-0042(22)01735-7
https://www.sciencedirect.com/science/article/pii/S2589004222017357
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618295/

ÂÛÎÄÖ¸³ö£º
1¡¢SARS-COV-2¸ÐȾÉϵ÷²¨Ðε°°×ÔÚϸ°û±íÃæµÄ±í´ï¡£

2¡¢SARS-COV-2¶ÔA549ϸ°ûµÄ¸ÐȾÄÜÁ¦Î¢Èõ£¬Ïà±È±í´ïACE2µÄVero E6ϸ°ûºÍCaco-2ϸ°û£¬A549ϸ°ûÖеÄSARS-COV-2¿½±´ÊýµÍ300±¶¡£A549ϸ°û¸ßˮƽ±í´ï²¨Ðε°°×£¬µ«²»±í´ïACE2¡£Õâ±íÃ÷²¨Ðε°°×²»ÄܶÀÁ¢½éµ¼SARS-COV-2¸ÐȾ¡£

S2589-0042(22)01735-7_gr2_lrg_40p_A.JPG

SARS-COV-2¶ÔVero E6¡¢Caco-2¡¢A549ϸ°ûµÄ¸ÐȾÄÜÁ¦

ÌáÐÑÁÐλעÒ⣬×Ý×ø±êµÄÉÏÏÂÁ½¶Î²»ÊǵȱÈÀýµÄ£¬ÌõÖù¸ß¶È±È²»´ú±í¸ÐȾÄÜÁ¦±È¡£

RQ£ºRelative Quantity£¬Ïà¶ÔÊýÁ¿£»

RQ£¨E gene£©£º£¨¸ÐȾ½øÈëϸ°ûÖеģ©SARS-COV-2 Eµ°°×»ùÒòµÄ£¨qPCR¼ì²â£©Ïà¶ÔÊýÁ¿¡£Eµ°°×¼´°üĤµ°°×£¨envelope£©¡£

S2589-0042(22)01735-7_gr1_lrg_30p_A_B.JPG

ͼA£ºÍ¨¹ýqPCR¼ì²âACE2¡¢TMPRSS2¡¢vimentinÔÚÈýÖÖϸ°ûÖеıí´ï·á¶È£»
ͼB£ºÍ¨¹ýÁ÷ʽϸ°ûÊõÆÀ¹Àϸ°ûÍâ±ívimentinµÄ±í´ï·á¶È£¬²¢±íʾΪƽ¾ùÓ«¹âÇ¿¶È£¨MFI£©¡£

MFI£ºmean fluorescence intensity£¬Æ½¾ùÓ«¹âÇ¿¶È¡£

3¡¢SARS-COV-2 Sµ°°×¡¢²¨Ðε°°×¡¢ACE2ÔÚÉÏƤϸ°û£¨Vero E6ϸ°û£©±íÃæÏ໥×÷Óã¬ÐγÉÈý·Ö×Ó¸´ºÏÎSARS-COV-2ͨ¹ýÈýÕßµÄÏ໥×÷ÓýøÈëϸ°û¡£µ±Ï¸°ûδ±»¸ÐȾʱ£¬¹Û²ì²»µ½²¨Ðε°°×ÓëACE2Ö®¼äµÄÏ໥×÷Óã¨VIM-ACE2µÄÏ໥×÷ÓÃÓëSARS-2¸ÐȾ¹Ò¹³£©¡£2¡¢3±íÃ÷£¬²¨Ðε°°×ÊÇSARS-COV-2µÄÖØÒªÊÜÌåACE2µÄ¹²ÊÜÌ壨¸¨ÖúÊÜÌ壩¡£

4¡¢Ï¸°û±íÃ沨Ðε°°×µÄ´æÔÚÓÐÀûÓÚSARS-COV-2¸ÐȾ¡£SARS-CoV-2¶ÔCaco-2ϸ°ûµÄ¸ÐȾЧÂʵÍÓÚVero E6ϸ°û£¨¼ûǰͼ£©¡£Caco-2ϸ°û¸ß±í´ïACE2µ«¼¸ºõ²»±í´ï²¨Ðε°°×£¬¶øVero E6ϸ°ûͬʱ¸ß±í´ïACE2ºÍ²¨Ðε°°×£¨¼ûÉÏͼ£©¡£

5¡¢ÒÖÖÆϸ°û±íÃæµÄ²¨Ðε°°×½µµÍÁËSARS-COV-2µÄϸ°û½øÈëºÍϸ°û¶¾ÐÔ¡£
a)Óò¨Ðε°°×½áºÏ¡¢¸ÉÈÅ¡¢ÖØ×é¼Áwithaferin A£¨WFA£©»ò¿¹²¨Ðε°°×V9µ¥¿Ë¡¿¹ÌåÔ¤´¦ÀíVero E6ϸ°û£¬¶¼¿ÉʹSARS-COV-2¸ÐȾ¼õÉÙ50%ÒÔÉÏ¡£
withaferin A£¨WFA£¬×íÇÑËØA£©ÊÇÒ»ÖÖÀà¹Ì´¼ÄÚõ¥£¬Äܹ»½áºÏ²¨Ðε°°×£¬ÈÅÂÒÆä±í´ï£¬²¢ÓÕµ¼²¨Ðε°°×ÔÚϸ°ûºËÖÜΧÖØ×éΪºËÖܾۼ¯Ìå¡£
b)Ïà±Èδ¾­´¦ÀíµÄVero E6ϸ°û£¬ÓÃWFA»òV9¿¹ÌåÔ¤´¦ÀíVero E6ϸ°ûÌá¸ßÁËϸ°û¸ÐȾºó48СʱµÄ»îÁ¦£¬Õâ±íÃ÷ÒÖÖƲ¨Ðε°°×¿ÉÒÔÒÖÖÆSARS-COV-2µÄϸ°û¶¾ÐÔ£¬¼õÉÙ»ò¼õ»ºÏ¸°ûËÀÍö¡£

6¡¢²¨Ðε°°×ÓëSARS-COV-2µÄÏ໥×÷Óõ÷½ÚÑ×ÐÔϸ°ûÒò×ÓºÍÇ÷»¯Òò×ӵıí´ï£¬¿¹²¨Ðε°°×V9µ¥¿Ë¡¿¹ÌåÔ¤´¦Àíµ¼ÖÂIL-6±í´ïϽµ15±¶£¬CCL5ºÍCXCL10±í´ïϽµ10±¶£¬ÕâЩÊý¾Ý±íÃ÷²¨Ðε°°×²ÎÓ루¡¢Ó°Ï죩SARS-CoV-2½éµ¼µÄϸ°ûËÀÍöºÍÉÏƤÑ×Ö¢·´Ó¦¡£

IL-6£¬Ò»ÖÖ¶àЧϸ°ûÒò×Ó£¬Ï¸°ûÒò×ӷ籩µÄÓÕÒò£»
CCL5£¬Ò»ÖÖÇ÷»¯Òò×Ó£¬ÓÕ·¢°×ϸ°û/ÃâÒßϸ°û¸½×ż°×ªÒÆÖÁ·¢Ñײ¿Î»£»
CXCL10£¬Ò»ÖÖÇ÷»¯Òò×Ó£¬ÊǻµÄTÁÜ°Íϸ°û¡¢µ¥ºËϸ°û¡¢¾ÞÊÉϸ°û¡¢×ÔȻɱÉËϸ°ûµÈ°×ϸ°û/ÃâÒßϸ°ûµÄ»¯Ñ§ÒýÓÕ¼Á£¬¿ÉÇ÷»¯ÉÏÊöϸ°ûµ½´ïÑ×Ö¢²¿Î»£¬·¢»Ó¿¹Ñ×ÃâÒß×÷Óá£CXCL10»ùÒòÒ²ÊÇÒ»ÖÖѪ¹ÜÒÖÖÆÒò×Ó¡£

7¡¢ÊµÑé±íÃ÷£¬²¨Ðε°°×ÓëSARS-CoV-2ԭʼ¶¾ÖêSµ°°×µÄÏ໥×÷Ó㬶Ôԭʼ¶¾Öê¸ÐȾµÄ´Ù½øÔÚomicron±äÌåÖеõ½Á˱£³Ö£¬¼´omicron±äÌåSµ°°×µÄһϵÁÐÍ»±äûÓиı䲨Ðε°°×ÓëSARS-CoV-2 Sµ°°×µÄÏ໥×÷Óã¬Ã»Óиı䲨Ðε°°×¶ÔSARS-CoV-2¸ÐȾÄÜÁ¦µÄ´Ù½ø×÷Óá£

8¡¢×ÜÖ®£¬ÎÒÃǵÄÊý¾Ý±íÃ÷£¬ÔÚSARS-COV-2¸ÐȾÖУ¬Ï¸°û±íÃ沨Ðε°°×ÊÇACE2µÄ¹²ÊÜÌå¡£

ÂÛÎÄÒÀ¾Ý¶þ

Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells
ϸ°ûÍⲨÐε°°×ÊÇ´Ù½øSARS-COV-2½øÈëÈËÄÚƤϸ°ûµÄ¸½×ÅÒò×Ó
https://www.pnas.org/doi/10.1073/pnas.2113874119

ÂÛÎÄÖ¸³ö£º
1¡¢Ê¹ÓÃÒºÏàÉ«Æ×-´®ÁªÖÊÆ×·¨£¨LC-MS/MS£©£¬¼ø¶¨³övimentin£¨VIM£©ÊÇÒ»ÖÖÓëSARS-CoV-2 Sµ°°×½áºÏµÄµ°°×ÖÊ£¬Sµ°°×ͨ¹ýÆäÊÜÌå½áºÏÓò£¨RBD£©Óëϸ°ûÍâ±íµÄVIMÏ໥×÷ÓᢽáºÏ£»VIMÔÚSARS-COV-2¸ÐȾÖг䵱ACE2µÄ¹²ÊÜÌ壨¸¨ÖúÊÜÌ壩¡£

2¡¢SARS-CoV-2¶ÔHEK-293ϸ°ûµÄ¸ÐȾÄÜÁ¦Î¢Èõ¡£HEK-293ϸ°û¼È²»±í´ïACE2£¬Ò²²»±í´ïVIM£¨²¨Ðε°°×£©£»
¶ÔתȾ±í´ïVIMµÄHEK-293ϸ°û£¬SARS-CoV-2µÄ¸ÐȾÄÜÁ¦Ã»ÓÐÃ÷ÏÔÌáÉý£»
¶ÔתȾ±í´ïACE2µÄHEK-293ϸ°û£¬SARS-CoV-2µÄ¸ÐȾÄÜÁ¦ÏÔÖøÌáÉý£»
¶ÔͬʱתȾACE2ºÍVIMµÄHEK-293ϸ°û£¬SARS-CoV-2µÄ¸ÐȾÄÜÁ¦½øÒ»²½ÌáÉý¡£
ÈçÏÂͼBËùʾ£º

pnas.2113874119fig03.jpg


¿É¼û£¬VIMÓëACE2µÄ¹²±í´ï´Ù½øSARS-CoV-2¶ÔHEK-293ϸ°ûµÄ¸ÐȾ£¬VIM¶ÔSARS-CoV-2¸ÐȾµÄ´Ù½øÒÀÀµÓÚACE2µÄ´æÔÚ¡£

¸Ã×é¸ÐȾʵÑéËùÓò¡¶¾ÎªÒÔSARS-CoV-2 Sµ°°×ǶºÏÖÆ×÷µÄ¼Ù²¡¶¾¡£

3¡¢VIM¡¢ACE2µÄ¿çϸ°û±í´ïÒ²ÄÜÏÔÖøÌáÉýSARS-CoV-2µÄ¸ÐȾ¡£½«VIM/HEK-293ϸ°û£¨×ªÈ¾±í´ïVIMµÄHEK-293ϸ°û£©ÓëACE2/A549ϸ°û£¨×ªÈ¾±í´ïACE2µÄA549 ϸ°û£©¹²ÅàÑøÏÔÖøÌáÉýÁËSARS-CoV-2¶ÔACE2/A549 ϸ°ûµÄ¸ÐȾ¡£ÈçÉÏͼHËùʾ¡£

4¡¢VIM¿ÉͬʱÓëSARS-COV-2 SºÍACE2Ï໥×÷Óã»VIMÓëACE2µÄÏ໥×÷ÓÃÌáÉýÁËSARS-COV-2 SÓëACE2µÄ½áºÏЧÂÊ£¬²¢Ê¹½áºÏ¸üÀι̣»SARS-2 S-RBDµÄVIM½áºÏλµã£¬ÓëS-RBDµÄACE2½áºÏλµã²»Í¬¡£

5¡¢Ò»ÖÖSARSÖкͿ¹ÌåCR3022¿Éʶ±ð¡¢½áºÏSARS-CoV-2-S-RBDÖеĶÀÌرí루ÈçÏÂͼAËùʾ£©£¬CR3022¿¹Ìå²»¸ÉÈÅ¡¢ÒÖÖÆSÓëACE2µÄ½áºÏ£¬µ«¸ÉÈÅ¡¢ÒÖÖÆSARS-2 S-RBDÓëVIMµÄ½áºÏ¡£Õâ±íÃ÷£¬SARS-2 S-RBD½áºÏVIMµÄ²¿Î»£¬ÓëÆä½áºÏCR3022¿¹ÌåµÄ²¿Î»´æÔÚÖغϡ£CR3022¿¹ÌåÊÇ´ÓSARS»¼Õ߻ָ´ÆÚѪ½¬Öмø¶¨³öÀ´µÄ¡£

6¡¢CR3022¿¹ÌåÒÖÖÆSARS-CoV-2¶ÔHUVEC-TERTϸ°ûµÄ¸ÐȾ£¬µ«µ±HUVEC-TERTϸ°ûÇõÍÁËVIM±í´ïʱ£¬CR3022¶ÔSARS-2¸ÐȾûÓÐÃ÷ÏÔµÄÒÖÖÆ×÷Ó᣼´CR3022¿¹Ìå¶ÔSARS-CoV-2¸ÐȾµÄÒÖÖƽö¶Ô³ä·Ö±í´ïVIMµÄϸ°ûÓÐЧ£¨CR3022ʵÖÊÉÏÊÇÔÚ¸ÉÈÅ¡¢ÒÖÖÆSARS-2 SÓëVIMµÄ½áºÏ£©¡£ÈçÏÂͼFËùʾ£º

pnas.2113874119fig05.jpg


HUVEC-TERT£ºhuman umbilical vein endothelial cells£¬ÈËÆê¾²ÂöÄÚƤϸ°û£»
VIM-shRNA/HUVEC-TERT£ºÍ¨¹ýshRNAÇõÍÁËVIM±í´ïµÄHUVEC-TERTϸ°û£»
shRNA£ºhort-hairpin RNA£¬¶Ì·¢¼ÐRNA £¬¿ÉÓÃÓÚ»ùÒò³ÁĬ£¬¸ÉÈÅ¡¢ÒÖÖÆÌض¨»ùÒò¡£

7¡¢Ïà¹ØʵÑé½øÒ»²½±íÃ÷£¬SARS-CoV-2¶Ô¹²±í´ïVIM ºÍACE2µÄHEK-293ϸ°ûµÄ¸ÐȾÂÊÃ÷ÏÔ¸ßÓÚ½ö±í´ïACE2µÄϸ°û£¨ÏÂͼA£©£»ÇõÍVIMÏÔÖøÒÖÖÆÁËSARS-CoV-2¶ÔHUVEC-TERTϸ°ûµÄ¸ÐȾ£¨ÏÂͼB£©¡£

pnas.2113874119fig06.jpg


8¡¢ÄÚƤϸ°ûÊÇSARS-CoV-2µÄÖ±½Ó¸ÐȾ°Ð±ê£¬ÄÚƤϸ°û¸ÐȾÒÔ¼°SARS-CoV-2ÓÕµ¼µÄÑ×Ö¢·´Ó¦¿Éµ¼Ö¶àÖÖÖ¢×´£¨ÆäÖÐÁ½ÖÖÊÇѪ¹ÜÉú³É¸Ä±äºÍÉñ¾­ÏµÍ³Ö¢×´£©¡£SARS-CoV-2ÓÕµ¼µÄÄÚƤËðÉË¡¢Ñª¹ÜѪ˨ÐγɺÍÄýѪ²¡£¬ÒÔ¼°·ëάÀÕ²¼À¼µÂÒò×ÓÉϵ÷£¬¶¼ÊÇÑÏÖØCOVID-19µÄÁÙ´²±êÖ¾¡£

9 ¡¢×ÜÖ®£¬VIMÊÇSARS-CoV-2µÄ¸½×ÅÒò×Ӻ͸¨ÖúÊÜÌ壬¿ÉÔöÇ¿ACE2ÒÀÀµÐÔ²¡¶¾½øÈ룬ÔÚSARS-CoV-2¸ÐȾÈËÄÚƤϸ°ûÖз¢»ÓÖØÒª×÷Óá£

ÂÛÎÄÒÀ¾ÝÈý

Extracellular Vimentin as a Target Against SARS©CoV©2 Host Cell Invasion
ϸ°ûÍⲨÐε°°×ÊÇSARS-COV-2ÇÖÏ®ËÞÖ÷ϸ°ûµÄ°Ð±ê
https://onlinelibrary.wiley.com/doi/full/10.1002/smll.202105640

ÂÛÎÄÖ¸³ö£º
1¡¢¶¯Ì¬¹âÉ¢ÉäÏÔʾ²¨Ðε°°×Óë´øÓÐSARS-CoV-2 Sµ°°×µÄ¼Ù²¡¶¾½áºÏ£»
2¡¢Õë¶Ô²¨Ðε°°×µÄ¿¹Ìå¿ÉÔÚÌåÍâ×è¶ÏSARS-CoV-2¼Ù²¡¶¾¶Ô±í´ïACE2µÄϸ°ûµÄ¸ÐȾ£»
3¡¢1¡¢2±íÃ÷ϸ°ûÍⲨÐε°°×ÊÇSARS-CoV-2µÄÊÜÌåACE2µÄ¹²Í¬ÊÜÌ壻
4¡¢SARS-CoV-2 Sµ°°×Ó벨Ðε°°×µÄ½áºÏÇ׺ÍÁ¦Ð¡ÓÚSµ°°×ÓëACE2µÄ½áºÏÇ׺ÍÁ¦£»
5¡¢Ï¸°ûÍⲨÐε°°×¿ÉÄÜ×÷ΪSARS-CoV-2 Sµ°°×-ACE2¸´ºÏÎïµÄ¹Ø¼ü³É·Ö£¬½éµ¼SARS-CoV-2½øÈëϸ°û£»
6¡¢²¨Ðε°°×°ÐÏòÒ©Îï¿ÉÄÜÔ¤·ÀºÍ¼õ»ºSARS-CoV-2¸ÐȾ¡£

ÂÛÎÄÒÀ¾ÝËÄ

Physicochemical Nature of SARS-CoV-2 Spike Protein Binding to Human Vimentin
SARS-COV-2´ÌÍ»µ°°×ÓëÈËÀನÐε°°×½áºÏµÄÎïÀí»¯Ñ§ÐÔÖÊ
https://pubs.acs.org/doi/10.1021/acsami.3c03347

ÂÛÎÄ¡°Conclusions¡±²¿·ÖÒëÎÄ´óÖÂÈçÏ£º
ʹÓÃAFM£¨atomic force microscopy£¬Ô­×ÓÁ¦ÏÔ΢¾µ£©ºÍQCM-D£¨quartz crystal microbalance with energy dissipation£¬¾ßÓÐÄÜÁ¿ºÄÉ¢µÄʯӢ¾§Ìå΢Ììƽ£©·½·¨£¬¶ÔSARS-CoV-2ԭʼ¶¾ÖêºÍÈýÖÖ±äÌ壨°ÍÎ÷¡¢ÄϷǺÍÓ¢¹ú£©µÄS1 RBDÓëVimÖ®¼äÏ໥×÷ÓõÄÉúÎïÁ¦Ñ§ºÍ¶¯Á¦Ñ§½øÐÐÁËÑо¿£¬ÎªS1 RBDÓëVimÏ໥×÷ÓõĻúеǿ¶ÈºÍÎȶ¨ÐÔÌṩÁËеÄÖ¤¾Ý¡£Ö¤ÊµÁËÏÈÇ°ÉúÎïѧÑо¿µÄ½á¹û£¬¼´È·¶¨VimÊDz¡¶¾½øÈëËÞÖ÷ϸ°ûµÄ¿ÉÄܸ½×ÅÃæ¡£´ËÍ⣬»¹¶ÔSARS-CoV-2¨CACE2ÓëVim¶þ¾ÛÌåÖ®¼äµÄ¼Ù¶¨Ï໥×÷Óó¡¾°½øÐÐÁËԭλ̽Ë÷£¬ÑéÖ¤ÁËVim-S1 RBDÓëACE2-S1 RBDÖ®¼ä¿ÉÄܵĽӴ¥²Ð»ù¡£ÎÒÃǵÄÑо¿½á¹û½«ÓÐÖúÓÚ³ä·ÖÁ˽ⲡ¶¾½øÈëËÞÖ÷ϸ°ûµÄ»úÖÆ¡¢¿ª·¢°²È«ÓÐЧµÄÔ¤·ÀÒÔ¼°ÖÎÁÆCovid-19µÄз½·¨¡£VimºÍ²¡¶¾Èںϵ°°×Ö®¼äµÄ½çÃæÏ໥×÷ÓÃÑо¿»¹¿ÉÓÃÓÚ¿ª·¢ÐµĹ¦ÄÜÐÔ¿¹²¡¶¾²ÄÁÏ»òÉú²úÄ£ÄâSARS-CoV-2²¡¶¾¿ÅÁ£µÄÄÉÃ×Á£×Ó£¬ÓÃÓÚ£¨±ãÀûµÄ£©ÊµÑéÊÒµÄÉúÎïÑо¿£¬ÎÞÐè´ïµ½´¦ÀíÌìÈ»SARS-CoV-2¶¾ÖêËùÐèµÄÉúÎﰲȫ¼¶±ð3£¬¿¼Âǵ½SARS-CoV-2²¡¶¾ºÍºóÐøÍ»±äÒýÆðµÄ¼²²¡ÔÚδÀ´¼¸Ä꽫¼ÌÐø³ÉΪҽѧÁìÓòµÄÖ÷ÒªÌôÕ½Ö®Ò»£¬ÕâÒ»µãÓÈΪÖØÒª¡£

ÆäËüÏà¹ØÂÛÎÄ

Vimentin as a target for the treatment of COVID-19
²¨Ðε°°××÷ΪCOVID-19ÖÎÁƵİеã
https://bmjopenrespres.bmj.com/content/7/1/e000623

Extracellular vimentin is sufficient to promote cell attachment, spreading, and motility by a mechanism involving N-acetyl glucosamine-containing structures
ϸ°ûÍⲨÐε°°××ãÒÔͨ¹ýÓ뺬N-ÒÒõ£ÆÏÌÑÌÇ°·½á¹¹Ïà¹ØµÄ»úÖÆÀ´´Ù½øϸ°û¸½×Å£¬À©É¢ºÍÔ˶¯
https://www.jbc.org/article/S0021-9258(23)01991-9/fulltext

£¨Î´Íê´ýÐø£©

0%(0)
0%(0)
±ê Ìâ (±ØÑ¡Ïî):
ÄÚ ÈÝ (Ñ¡ÌîÏî):
ʵÓÃ×ÊѶ
±±ÃÀ×î´ó×îÈ«µÄÕÛ¿Û»úƱÍøÕ¾
ÃÀ¹úÃû³§±£½¡Æ·Ò»¼¶´úÀí,»¨Æì²Î,άËûÃü,ÓãÓÍ,ÂÑÁ×Ö¬,30ÌìÍË»õ±£Ö¤.Âò°ÙÃâÓÊ.
Ò»Öܵã»÷ÈÈÌû ¸ü¶à>>
Ò»Öܻظ´ÈÈÌû
ÀúÊ·ÉϵĽñÌ죺»Ø¸´ÈÈÌû
2022: #taiwan #²ÌÓ¢ÎÄ #¶Ø´Ù²ÌÓ¢Îļ°ÆäÜŠÕþÊ×
2022: ÀúÊ·Ö¤Ã÷£¬Ã«Ô󶫶ÔÁË
2021: Ë­ÐèÒªµÐÈË Ë­ÐèÒªÕ½Õù
2021: ÖйúÈËÓÖÆ®ÁË
2020: ÌìÌÃ
2020: Ó¢ÐÛ
2019: ´ÓÖй²Î¥ÏÜ-¹úÌ©CEO¡°±»´ÇÖ°¡±¿´ÖйúÕþ
2019: ´ÓÏã¸ÛÈý²»Òª¿ú²âºìǽÄÚ¶¯Ïò
2018: ÒɵãÖØÖصÄÖì¾ü°¸
2018: Õ½Õù±³ºóµÄÕ½Õù£¬ÃÀ¹úÄóסÖйúÆß´ç